Y0000401
Pimobendan for system suitability
European Pharmacopoeia (EP) Reference Standard
别名:
Pimobendan, 4,5-Dihydro-6-[2-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-5-methyl-3(2H)-pyridazinone
登录查看公司和协议定价
所有图片(1)
About This Item
经验公式（希尔记法）:
C19H18N4O2
CAS号:
分子量:
334.37
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24
推荐产品
![4-Chloro-N-[2-(4-hydroxyphenyl)ethyl]benzamide AldrichCPR](/deepweb/assets/sigmaaldrich/product/structures/139/662/1ce3ff3b-f928-4434-88d9-f4981db0fc47/640/1ce3ff3b-f928-4434-88d9-f4981db0fc47.png)
等级
pharmaceutical primary standard
API类
pimobendan
制造商/商品名称
EDQM
应用
pharmaceutical (small molecule)
包装形式
neat
储存温度
2-8°C
SMILES字符串
CC(C(C1=CC=C(NC(C2=CC=C(OC)C=C2)=N3)C3=C1)=NN4)CC4=O
InChI
1S/C19H18N4O2/c1-11-9-17(24)22-23-18(11)13-5-8-15-16(10-13)21-19(20-15)12-3-6-14(25-2)7-4-12/h3-8,10-11H,9H2,1-2H3,(H,20,21)(H,22,24)
InChI key
GLBJJMFZWDBELO-UHFFFAOYSA-N
正在寻找类似产品? 访问 产品对比指南
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
应用
Pimobendan for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
包装
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他说明
Sales restrictions may apply.
警示用语：
Danger
危险声明
危险分类
Acute Tox. 3 Oral
储存分类代码
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
John M Macgregor et al.
Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology, 13(4), 251-260 (2011-10-28)
To describe the therapeutic use of pimobendan in cats, describe the patient population to which it was administered, document potential side effects and report the clinical course following administration of pimobendan in conjunction with standard heart failure therapy. It is
S Suzuki et al.
Journal of veterinary internal medicine, 25(6), 1328-1333 (2011-11-19)
The effects of pimobendan on left atrial pressure (LAP) in dogs with mitral valve disease (MR) have not been documented in a quantitative manner. The objective was to document and study the short-term effects of pimobendan on LAP and echocardiographic
Scott R Helms et al.
International journal of pharmaceutical compounding, 16(1), 34-41 (2012-10-12)
Pimobendan (Vetmedin) is an effective treatment for canine chronic degenerative mitral valve disease and dilated cardiomyopathy. In an off-label use, it may also be of benefit for the treatment of pulmonary hypertension in dogs. In this report, we describe the
L Noelani Reinker et al.
Journal of the American Animal Hospital Association, 48(4), 250-255 (2012-05-23)
The purpose of this study was to review the medical records of dogs that were either suspected or known to have ingested large doses of pimobendan and to describe the clinical signs associated with pimobendan toxicosis. The database of Pet
[Calcium mobilizers and calcium sensitizers].
Masashi Arai
Nihon rinsho. Japanese journal of clinical medicine, 69 Suppl 9, 417-422 (2012-06-26)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门